

Figure S4




Figure S4: Loss of stromal IL-33 alters the ST2⁺ immune cell secretome, resulting in a shift in CAF differentiation. (A) Expression of *Areg* and *Egfr* across cell types in the *CreER* and *CreER;Il33^{ff}* scRNAseq datasets. (B) Immunostaining of *CreER* and *CreER;Il33^{ff}* tumors. Top = Gomori trichrome staining, bottom = Co-IF staining of PDGFR α/β (green), α -SMA (magenta), and DAPI (blue); arrows denote representative PDGFR α/β ⁺ α -SMA⁺ cells (yellow) or PDGFR α/β ⁺ α -SMA⁻ cells (white). (C) Diagram depicting generation and treatment of IL-33 WT and IL-33 KO fibroblast lines. (D) Protein expression from fibroblasts in (C). (E) GSEA enrichment plots from bulk RNAseq of fibroblasts from (C). (F) Proliferation of IL-33 WT and KO fibroblasts with and without PDA CM treatment. (G) Gene expression of differentially expressed ligands from **Figure 3H** grouped by CAF subtype and split by experimental group. For staining quantification, each dot represents one animal, and values were compared using two-tailed Student's *t* test. Histogram data are mean \pm standard deviation.